Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIVV020 for Prevention and Treatment of Antibody-mediated Rejection in Kidney Transplant
NCT05156710Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jun 2022
- Primary completion
- Oct 2025
- Modality
- IgG Antibodies
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of riliprubart in transplant rejection (3 cohorts), sponsored by Sanofi. Primary endpoints: Treatment failure rate and Antibody-mediated rejection resolution rate. Started Jun 2022; status: active, not recruiting.
02
Drugs
riliprubart
03
Conditions
transplant rejection
Beyond the preview
Go deeper on NCT05156710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05156710.